Moreover, recent studies have identified the AIP as a robust biomarker of dyslipidemia, with higher levels suggesting more severe insulin resistance (IR) (Shi and Wen, 2023; Yin et al., 2023). The gene discussed is AIP; the disease is metabolic syndrome.